Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

The International Working Group discussed diagnosing Alzheimer's disease among cognitively unimpaired individuals in a ...

Alzheimer’s is the most common type of dementia. Music therapy can improve mood and cognitive performance in Alzheimer’s ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.

Italian researchers have developed a nasal spray showing promise in slowing Alzheimer's progression. Tests on mice with ...

Subtle signs of Alzheimer's disease can emerge decades before a diagnosis—often in the form of irregular behaviors that ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

I want to express my gratitude to Sen. Bob Casey for his steadfast dedication to the fight against Alzheimer’s disease during ...

The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...

The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

APOE4 carriers had higher blood-brain barrier permeability, even without cognitive decline or amyloid beta buildup, ...